• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Modalities to enumerate circulating tumor cells in the bloodstream for cancer prognosis and to monitor the response to the therapy.
【24h】

Modalities to enumerate circulating tumor cells in the bloodstream for cancer prognosis and to monitor the response to the therapy.

机译：酶促血液肿瘤细胞在血液中的癌症预后和监测治疗响应的态度。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Certain malignant cells may detach from the primary tumor and enter the vascular system, forming so-called circulating tumor cells (CTCs). Clusters of malignant cells associated with other cell types can also be observed in the peripheral blood of oncological patients. Such cell clusters are termed circulating tumor microemboli (CTM). The isolation and quantification of CTCs and/or CTM from blood samples allow for an accurate prognosis of the clinical course of the disease and to monitor the response to therapy. Current protocols rely on epithelial markers for the isolation of CTCs and/or CTM from hematopoietic cells. However, epithelial markers may be silenced during the progression of the epithelial-mesenchymal transition, which regulates the detachment and migration of malignant cells from the primary tumor. This review summarizes the achievements and challenges of various modalities for the isolation, enrichment, analysis and enumeration of CTCs and/or CTM, in order to assess the advancement of the disease and the response to therapy.
机译：某些恶性细胞可以从原发性肿瘤脱离并进入血管系统，形成所谓的循环肿瘤细胞（CTC）。在肿瘤患者的外周血中也可以观察到与其他细胞类型相关的恶性细胞簇。这种细胞簇被称为循环肿瘤微栓（CTM）。来自血液样本的CTC和/或CTM的分离和定量允许对疾病的临床过程进行准确预后，并监测对治疗的反应。目前的方案依赖于上皮标记物用于分离造血细胞的CTC和/或CTM。然而，上皮 - 间充质转变期间的上皮标记物可以沉默，其调节来自原发性肿瘤的恶性细胞的分离和迁移。本综述总结了各种方式对CTCS和/或CTM的分离，富集，分析和计数的各种方式的成就和挑战，以评估疾病的进步和对治疗的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号